OTHER INFORMATION
of 'Ceritinib'
|
| Purity : |
Not less than 95% |
| Therapeutic : |
Anti-Cancer / Oncology |
| Purity : |
Not less than 95% |
| Therapeutic : |
Anti-Cancer / Oncology |
| IUPAC Name : | 5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine |
| Chemical name of this compound, computed from its structure based on the International Union of Pure and Applied Chemistry (IUPAC) nomenclature standards. |
| Applicationnotes : | Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. |
| Synonym : | 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine |
| References : | "Medscape, April 29, 2014; Engelman JA (2014)" |
| Smileys : | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl |
| Appearance : | White to off-white solid |
| Use Classification : | Human drugs -> Zykadia -> EMA Drug Category |
| This section contains use classification/category information for this compound from various sources. |
| Hazard Class : | Acute Tox. 4 (33.33%) |
| The Hazard Classes and Categories are aligned with GHS (Globally Harmonized System of Classification and Labelling of Chemicals) hazard statement codes. |
| EC Number : | 811-457-8 |
| The European Community (EC) number is a seven-digit identifier assigned by the European Chemicals Agency (ECHA) to substances for regulatory purposes within the European Union. EC numbers are sometimes referred to as EINECS, ELINCS, or NLP numbers |
| UNII : | K418KG2GET |
| UNique Ingredient Identifier (UNII) code for this chemical. It is a non-proprietary registry number assigned by the U.S. Food and Drug Administration (FDA). |
| NCI Thesaurus Code : | C115112 |
| Stable, unique code for biomedical concept |
| RXCUI : | 1535457 |
| Stable, unique code for biomedical concept |
| MeSH Entry Terms : | 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine |
| Medical Subject Heading (MeSH) names or identifiers matching this PubChem Compound record. The matching between the MeSH and compound records is performed by name matching (i.e., identical common names) |
| Other Synonyms : | ceritinib |
| Removed Synonyms : | Ceritinib dihydrochloride |
| Label Ingredient : |
CERITINIB |
| Active ingredient(s) of the drug product. |
| NDC Code : | 0078-0694-48, 0078-0694-84 |
| U.S. Food & Drug Administration (FDA)'s National Drug Code (NDC) for the drug product. |
| Toxicity Summary : | There is not currently any data on carcinogenicity, effect on human fertility, or on early embryonic development. However, based on its mechanism of action, ceritinib may cause fetal harm when administered to pregnant women and should therefore be administered with effective contraception during treatment. Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients. Drug-induced hepatotoxicity also occurred in 27% of 255 patients, presenting as alanine aminotransferase (ALT) levels greater than 5 times the upper limit of normal (ULN). Severe, life-threatening, or fatal interstitial lung disease (ILD)/pneumonitis, hyperglycaemia, and bradycardia have also been reported. |
| Summary of the toxicity of this compound, provided by the Hazardous Substances Data Bank (HSDB). |
| Hepatotoxicity : | Elevations in serum aminotransferase levels are common during ceritinib therapy occurring in 20% to 50% of patients, but rising above 5 times the upper limit of the normal range in only 1% to 2%. Hepatic failure is said to have occurred in 0.2% of patients and to have resulted in several fatalities. Hepatotoxicity appears to be a class effect among ALK inhibitors, although liver injury appears to be more frequent and more severe with crizotinib than ceritinib or alectinib. Specific details of the liver injury associated with ceritinib such as latency, serum enzyme pattern, clinical features and course, have not been published. Other ALK inhibitors typically cause liver injury arising within days or weeks of starting therapy, and presenting abruptly with hepatocellular enzyme elevations and a moderate-to-severe course. Immunoallergic and autoimmune features are not common. The rate of clinically significant liver injury and hepatic failure is increased in patients with preexisting cirrhosis or hepatic impairment due to liver tumor burden. Recurrence upon reexposure has been reported. |
| This section provides a short description about the hepatotoxicity associated with this compound, the rate of serum enzyme elevations during use, and the frequency and character of the clinically apparent liver injury associated with the compound. |
| Protein Binding : | Ceritinib is 97% bound to human plasma proteins, independent of drug concentration. |
| In this section, "protein binding" refers to the degree to which medications attach to plasma proteins (i.e., proteins within the blood, such as human serum albumin, lipoprotein, glycoprotein and globulins) |
| Exact Mass : | 557.2227389 |
| The exact mass of an isotopic species is obtained by summing the masses of the individual isotopes of the molecule. |
| InChI : | InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) |
| The International Chemical Identifier (InChI) is a computed, non-proprietary identifier for a chemical structure. The InChI is an International Union of Pure and Applied Chemistry (IUPAC) standard. |
| InchIKey : | VERWOWGGCGHDQE-UHFFFAOYSA-N |
| An InChIKey is a 27-character hash code derived from an InChI. The International Chemical Identifier (InChI) is a computed, non-proprietary identifier for a chemical structure. |
| Canonical SMILES : | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl |
| The Simplified Molecular-Input Line-Entry System (SMILES) is a widely-used line notation for chemical structures. |
| Isomeric SMILES : | CC1=CC(=C(C=C1C2CCNCC2)OC(C)C)NC3=NC=C(C(=N3)NC4=CC=CC=C4S(=O)(=O)C(C)C)Cl |
| The Simplified Molecular-Input Line-Entry System (SMILES) is a widely-used line notation for chemical structures. |
| Product Description : | Ceritinib is a member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer. It has a role as an antineoplastic agent and an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor. It is an aminopyrimidine, an aromatic ether, an organochlorine compound, a secondary amino compound, a member of piperidines and a sulfone. |
| Custom Duty : |
Applicable |
| Port of Loading : |
Canada |
| Expected Dispatch : |
15-Aug-2022 |
| Taxes : |
Not Applicable |
| Refund Policy : |
30-days money back |
| Custom Duty : |
Applicable |
| Port of Loading : |
Canada |
| Expected Dispatch : |
15-Aug-2022 |
| Taxes : |
Not Applicable |
| Refund Policy : |
30-days money back |
